Austin Angelidakis NP (He/Him)

Abstracts/Posters

• A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.
  Jindal, T., Han, H., Deshmukh, P. S., De Kouchkovsky, I., Kwon, D., Borno, H. T., Koshkin, V. S., Desai, A., Bose, R., Chou, J., Friedlander, T., Small, E. J., Angelid..., European Society for Medical Oncology, Paris, France, 9/1/2022
• A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)
  Aggarwal, R., Trihy, L., Hernandez Romero, E., Luch Sam, S., Rastogi, M., De Kouchkovsky, I., Small, E. J., Feng, F., Kwon, D., Friedlander, T., Borno, H. T., Bose, R...., European Society for Medical Oncology, Paris, France, 9/1/2022
• Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC).
  Neelima Vidula, Jimmy Hwang, Sally Greenberg, Michelle E. Melisko, Andrei Goga, Mark Moasser, Ariadna Gasol Cudos, Austin Nicholas Angelidakis, Amy DeLuca, Laura A Pet..., American Society of Clinical Oncology, Chicago, Illinois, 5/30/2017
• Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC).
  Melanie Catherine Majure, Ariadna Gasol Cudós, Austin Nicholas Angelidakis, Michelle E. Melisko, Ariel R. Karwat, Amy Jo Chien, Andrei Goga, Mark M. Moasser, John W. P..., American Society of Clinical Oncology, Chicago, Illinois, 5/20/2016
• Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NC...
  Manuela Terranova Barberio, Scott Thomas, Amy Jo Chien, Hope S. Rugo, Michelle E. Melisko, Austin Nicholas Angelidakis, Nela Pawlowska, Travis Deal, Pamela N. Munster, American Society of Clinical Oncology, Chicago, Illinois, 5/20/2016
• Join now to see all